

4<sup>th</sup> International Conference on

# Clinical Trials

 September 11-13, 2017 San Antonio, USA

## Insurance considerations for global clinical trials

**Brian M Toglia**

Tanner-Ibbotson, Inc., USA

A key component of international clinical trials that is often overlooked is insurance considerations for the country where the study will be performed. Failure to comply with jurisdictional or IRB insurance requirements can delay approval for the start of a trial. In drug development, any delay could cost the sponsor millions of dollars. Having the proper insurance program structure is also critical to avoid any gaps in protection. Working with a qualified insurance broker that has key relationship with global insurance companies is critical. A proactive approach and understanding of the parameters of insurance procurement for global clinical trial will produce a well-managed clinical trials insurance process as it relates to efficiency, affordability, protection and ease of administration.

### Biography

Brian M Toglia is Principal and Vice President at Tanner-Ibbotson, Inc., an insurance brokerage located in the Northeast part of the United States. With a focus on providing insurance solutions for pharmaceutical and medical device companies, he brings over a decade of experience in the industry. His practice helps companies procure insurance both domestically and internationally. He holds a Bachelors' degree in Business Administration and Political Science from Pepperdine University in Southern California.

btoglia@tanneribbotson.com

### Notes: